Johnson & Johnson (JNJ) Is One Of Jim Cramer’s Top Performing 2026 Stocks

We recently published Jim Cramer’s Biggest Winners to Buy: Top 20 AI & Other Stocks He Got Right in 2026. Johnson & Johnson (NYSE:JNJ) is one of the stocks discussed by Jim Cramer.

Healthcare giant Johnson & Johnson (NYSE:JNJ)’s shares are up by 68% over the past year and by 26% year-to-date. The firm reported its fourth quarter earnings on January 21st. It posted $24.56 billion in revenue and $2.46 in earnings per share to beat analyst estimates. Crucially, Johnson & Johnson (NYSE:JNJ) also forecast full year revenue to range between $99.5 billion and $100.5 billion and full year profit per share to sit between $11.43 to $11.63 to beat analyst estimates for both metrics. Cramer has been increasingly optimistic about Johnson & Johnson (NYSE:JNJ) for nearly a year now. Some factors that have caught his attention include a robust oncology portfolio and overall business streamlining. On April 14th, Johnson & Johnson (NYSE:JNJ)’s first quarter earnings saw it post $24.1 billion in revenue and $2.70 in adjusted earnings to beat analyst estimates. It also raised its full year guidance again. Here is what Cramer said about the firm in January:

Trong Nguyen / Shutterstock.com

“The fastest grower, the best opportunity here would not be Eli Lilly, which has moved a great deal and I still like, but Johnson & Johnson. It’s spinning off its orthopedics business, DePuy Synthes, something that will immediately raise its price-to-earnings multiple because that business has much slower growth than the core pharma franchise. Same thing happened when J&J spun off Kenvue, its over-the-counter drug business. Great move to raise the valuation. At one point, this stock was down more than $5 today. I think it’s a terrific entry point even down three.”

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy.

Disclosure: None. Follow Insider Monkey on Google News.